Ennature Bio Pharma Q2 FY27: Revenue Rs 7,845.87 lakh; PAT Rs 488.68 lakh
Ennature Bio Pharma’s standalone Q2 FY27 revenue was Rs 7,845.87 lakh and PAT Rs 488.68 lakh versus Rs 5,414.14 lakh and loss of Rs (128.19) lakh a year earlier.
Key takeaways
- Revenue from operations Rs 7,845.87 lakh vs Rs 5,414.14 lakh a year earlier.
- Total expenses Rs 7,184.72 lakh vs Rs 5,550.18 lakh in the corresponding quarter.
- EBIDTA Rs 1,033.73 lakh vs Rs 603.86 lakh in the year-ago quarter.
- PAT Rs 488.68 lakh vs loss of Rs (128.19) lakh in Q2 FY26.
- Basic and diluted EPS Rs 2.19 vs Rs (0.57) a year earlier.
Q2 FY27 · standalone
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 7,845.87 lakh | Rs 5,414.14 lakh | +44.9% |
| PAT | Rs 488.68 lakh | Rs (128.19) lakh | +481.3% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
-
Net margin was 6.23% of revenue, up 859 bps from -2.37%.
-
Revenue rose 44.9% while total expenses rose 29.5%.
-
Changes in inventories accounted for Rs 1,050.90 lakh of the Rs 1,634.54 lakh rise in total expenses (64%).
-
Cost of materials took 39.6% of revenue, against 52.6% a year earlier.
-
Basis: Standalone statement of unaudited financial results
-
Period reported: Quarter ended 30.09.2026 (Q2 FY27)
-
Comparative period: Quarter ended 30.09.2025
-
Revenue from operations: Rs 7,845.87 lakh (Q2 FY27) vs Rs 5,414.14 lakh (Q2 FY26)
-
Total income: Rs 7,845.87 lakh vs Rs 5,414.14 lakh
-
Cost of materials consumed: Rs 3,109.05 lakh vs Rs 2,850.10 lakh
-
Changes in inventories of finished goods, Stock-in Trade and work-in-progress: Rs 1,377.06 lakh vs Rs 326.16 lakh
-
Employee benefits expense: Rs 746.18 lakh vs Rs 600.21 lakh
-
Finance costs: Rs 2.50 lakh vs Rs 378.85 lakh
-
Depreciation and amortisation expense: Rs 370.08 lakh vs Rs 361.05 lakh
-
Power and fuel: Rs 453.45 lakh vs Rs 276.14 lakh
-
Other expenses: Rs 1,126.40 lakh vs Rs 757.67 lakh
-
Total expenses: Rs 7,184.72 lakh vs Rs 5,550.18 lakh
-
Profit Before Interest, Depreciation and Tax (EBIDTA): Rs 1,033.73 lakh vs Rs 603.86 lakh
-
Profit / (Loss) from operations before exceptional items and tax (1-2): Rs 661.15 lakh vs Rs (136.04) lakh
-
Exceptional items: Rs - vs Rs -
-
Profit / (Loss) before Tax (3-8): Rs 661.15 lakh vs Rs (136.00) lakh
-
Current tax: Rs 81.78 lakh vs Rs -
-
Deferred tax: Rs 90.69 lakh vs Rs (7.85) lakh
-
Profit / (Loss) for the period (PAT): Rs 488.68 lakh vs Rs (128.19) lakh
-
Paid-up Equity Share Capital (Face value Rs. 5/- each): Rs 1,117.11 lakh vs Rs 1,117.11 lakh
-
Earnings per equity share – Basic (Not annualised): Rs 2.19 vs Rs (0.57)
-
Earnings per equity share – Diluted (Not annualised): Rs 2.19 vs Rs (0.57)
According to the statement of unaudited financial results for the quarter and half year ended September 30, 2026, Ennature Bio Pharma Limited reported standalone revenue from operations of Rs 7,845.87 lakh for the quarter ended 30.09.2026, compared with Rs 5,414.14 lakh in the corresponding quarter ended 30.09.2025. Total income for the quarter was also Rs 7,845.87 lakh, as no other income was reported in either period.
Total expenses rose to Rs 7,184.72 lakh in Q2 FY27 from Rs 5,550.18 lakh in Q2 FY26. Within this, cost of materials consumed increased to Rs 3,109.05 lakh from Rs 2,850.10 lakh, and changes in inventories of finished goods, stock-in trade and work-in-progress moved to Rs 1,377.06 lakh from Rs 326.16 lakh. Employee benefits expense rose to Rs 746.18 lakh from Rs 600.21 lakh, depreciation and amortisation expense to Rs 370.08 lakh from Rs 361.05 lakh, power and fuel to Rs 453.45 lakh from Rs 276.14 lakh, and other expenses to Rs 1,126.40 lakh from Rs 757.67 lakh. Finance costs were Rs 2.50 lakh in Q2 FY27 versus Rs 378.85 lakh a year earlier.
Profit Before Interest, Depreciation and Tax (EBIDTA) for the quarter was Rs 1,033.73 lakh, compared with Rs 603.86 lakh in the corresponding previous quarter. Profit / (Loss) from operations before exceptional items and tax (1-2) improved to Rs 661.15 lakh from a loss of Rs (136.04) lakh. There were no exceptional items reported in either quarter. Profit / (Loss) before tax (3-8) was Rs 661.15 lakh in Q2 FY27 versus a loss of Rs (136.00) lakh in Q2 FY26.
After accounting for current tax of Rs 81.78 lakh and deferred tax of Rs 90.69 lakh (versus deferred tax credit of Rs (7.85) lakh and no current tax in the prior period), Profit / (Loss) for the period stood at Rs 488.68 lakh, compared with a loss of Rs (128.19) lakh a year earlier. The paid-up equity share capital remained Rs 1,117.11 lakh in both periods. Basic and diluted earnings per equity share (face value Rs 5/- each, not annualised) were Rs 2.19 in Q2 FY27, versus Rs (0.57) in Q2 FY26, as per the statement of financial results.
Get Ennature Bio Pharma Ltd's next results the minute they're filed
Results reach the exchange at all hours, most of them after the market closes. Pro puts the filing in your feed as it is published, with our read of the numbers. A free account sees it an hourback for a day.
- We'll start you off following ENNATURE.
- 14 days free, no card. After that you keep a free account.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.